← All Nkgen Biotech, INC filings

Nkgen Biotech, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

OTC.Pink
NKGN
Nkgen Biotech, INC
10-Q: NKGen Biotech Reports Q1 Net Income Amidst Delisting & Debt Defaults
NKGen Biotech reported a net income of $15.35 million for Q1 2025, primarily driven by non-cash gains, while facing significant liquidity challenges, debt defaults, and a delisting from Nasdaq.
OTC.Pink
NKGN
Nkgen Biotech, INC
10-Q: NKGen Biotech Reports Q3 2024 Results, Navigates Financial Challenges
NKGen Biotech's Q3 2024 results reveal a complex financial landscape marked by a net income of $6.6 million alongside ongoing efforts to secure additional funding and address going concern uncertainties.
OTC.Pink
NKGN
Nkgen Biotech, INC
10-Q: NKGen Biotech Reports Second Quarter 2024 Results Amidst Financial Restructuring
NKGen Biotech's second quarter 2024 results reveal ongoing losses and significant financial activity, including debt and equity transactions, as the company navigates its clinical development and public company status.
OTC.Pink
NKGN
Nkgen Biotech, INC
10-Q: NKGen Biotech Reports First Quarter 2024 Results Amidst Financial Restructuring
NKGen Biotech's first quarter 2024 results reveal ongoing losses and significant financial activity, including debt issuances and amendments to forward purchase agreements.